Myeloid Differentiation Treatment to Diminish the Presence of Immune-Suppressive CD34+ Cells Within Human Head and Neck Squamous Cell Carcinomas

Journal of Immunology

Volumn 159, Issue 2, 1997, Pages 990-996

  Young, M Rita I ^a,b   Wright, Mark A ^a   Pandit, Rajiv ^b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECT; HEAD AND NECK TUMOR; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD34; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; HEAD AND NECK NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSION; INTERFERON TYPE II; LEUKOCYTES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031570886     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hadden, J. W., J. Endicott, P. Baekey, P. Skipper, and E. M. Hadden. 1994. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 120:395.
2. Clayman, G. L., D. L. Taylor, F. J. Liu, P. Lavedan, H. E. Savage, and S. P. Schantz. 1993. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells. Laryngoscope 103:299.
3. Katz, A. E. 1993. Update on immunology of head and neck cancer. Med. Clin. North Am. 77:625.
4. Vlock, D. R. 1991. Immunobiologic aspects of head and neck cancer. Hematol. Oncol. Clin. North Am. 5:797.
5. Kerrebijn, J. D., P. J. Simons, M. Tas, A. J. Balm, and H. A. Drexhage. 1995. In vivo effects of thymostimulin treatment on monocyte polarization, dendritic cell clustering and serum p15E-like trans-membrane factors in operable head and neck squamous cell carcinoma patients. Eur. Arch. Otorhinolaryngol. 252:409.
6. Gooding, R., P. Riches, G. Dadian, J. Moore, and M. Gore. 1995. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br. J. Cancer 72:452.
7. O'Mahony, A. M., G. C. O'Sullivan, J. O'Connell, T. G. Cotter, and J. K. Collins. 1993. An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J. Immunol. 151:4847.
8. Lapointe, H., H. Lampe, and D. Banerjee. 1992. Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses. Otolaryngology 106:149.
9. Rice, S. Q., I. J. Crane, C. Scully, and S. S. Prime. 1992. Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. Scand. J. Immunol. 36:443.
10. Chakraborty, N. G., M. T. Ergin, and B. Mukherji. 1991. Suppressor function of lymphocytes activated in in vitro co-culture against autologous tumor cells and expanded in interleukin-2. In Vivo 5:631.
11. Koyama, S. and K. Fukao. 1994. Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma. J. Cancer Res. Clin. Oncol. 120:240.
12. Alleva, D. G., C. J. Burger, and K. D. Elgert. 1994. Tumour growth causes suppression of autoreactive T-cell proliferation by disrupting macrophage responsiveness to interferon-γ Scand. J. Immunol. 39:31.
13. Maeda, N., and Y. Sagara. 1993. Analysis of immunosuppressive mechanism to cytotoxic T lymphocyte generation in patients with advanced cancer. Asia Oceania J. Obstet. Gynaecol. 19:309.
14. Wanebo, H. J., T. Riley, D. Karz, R. C. Pace, M. E. Johns, and R. W. Cantrell. 1988. Indomethacin sensitive suppressor-cell activity in head and neck cancer patients: the role of the adherent mononuclear cell. Cancer 61:462.
15. Farinas, M. C., V. Rodriguez-Valverde, M. T. Zarrabeitia, J. A. Parra-Blanco, and J. Sanz-Ortiz. 1991. Contribution of monocytes to the decreased lymphoproliferative response to phytohemagglutinin in patients with lung cancer. Cancer 68: 1279.
16. Kaffenberger, W., L. Holzer-Muller, T. Auberger, B. P. Clasen, G. Hohlmeier, and D. van Beuningen. 1995. An immunological outcome predictive score for head and neck carcinoma patients. Strahlenther. Onkol. 171:444.
17. + cells in cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1:95.
18. Young, M. R. I., M. A. Wright, Y. Lozano, J. P. Matthews, J. Benefield, and M. M. Prechel. 1996. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer 67:333.
19. Joraschkewitz, M., H. Depenbrock, M. Freund, G. Erdmann, H.-J. Meyer, W. De Riese, D. Neukam, U. Hanauske, M. Krumwieh, H. Poliwoda, and A.-R. Hanauske. 1992. Effects of cytokines on in vitro colony formation of primary human tumour specimens. Eur. J. Cancer 26:1070.
20. Pavel, P. E. Halapi, E. K. Pisa, E. Gerdin, C. Hising, A. Bucht, B. Gerdin, and R. Kiessling. 1992. Selective expression of interleukin 10, interferon γy, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc. Natl. Acad. Sci. USA 89:7708.
21. Lang, S. H., W. R. Miller, W. Duncan, and F. K. Habib. 1994. Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor. Int. J. Cancer 59:235.
22. 3 plus γ-interferon blocks lung tumor production of granulocyte-macrophage colony-stimulating factor and induction of immunosuppressor cells. Cancer Res. 53:6006.
23. Sawyers, C. L., D. W. Golde, S. Quan, and S. D. Nimer. 1992. Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia. Cancer 69:1342.
24. Berdel, W. E., S. Danhauser-Riedl, D. Oberberg, and M. Zafferani. 1992. Effects of hematopoietic growth factors on malignant nonhematopoietic cells. Semin. Oncol. 19:41.
25. Mann, E. A., J. D. Spiro, L. L. Chen, and D. L. Kreutzer. 1992. Cytokine expression by head and neck squamous cell carcinomas. Am. J. Surg. 164:567.
26. 3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett. 104:153.
27. Young, M. R. I., M. A. Wright, J. P. Matthews, I. Malik, and M. Prechel. 1996. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J. Immunol. 156:1916.
28. Brooks-Kaiser, J. C., L. A. Bourque, and D. W. Hoskin. 1993. Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharmacology 25:117.
29. Schmidt-Wolf, I. G., S. Dejbakhsh-Jones, N. Ginzton, P. Greenberg, and S. Strober. 1992. T-cell subsets and suppressor cells in human bone marrow. Blood 80:3242.
30. Young, M. R. I., and M. A. Wright. 1992. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: interferon-γ plus tumor necrosis factor-α synergistically reduce immune suppressor and tumor growth-promoting activities of bone marrow cells, and diminish tumor recurrence and metastasis. Cancer Res. 52:6335.
31. Brooks-Kaiser, J., and D. W. Hoskin. 1993. Inhibition of DNA synthesis and IL-2 bioactivity in MLR by splenic pregnancy-associated natural suppressor cells involves the production of a TGF-β1-like molecule and a second distinct inhibitory factor. J. Reprod. Immunol. 25:31.
32. Field, E. H., and G. C. Becker. 1992. Blocking of mixed lymphocyte reaction by spleen cells from total lymphoid-irradiated mice involves interruption of the IL-2 pathway. J. Immunol. 148:354.
33. Moore, S. C., S. A. Theus, J. B. Barnett, and L. S. Soderberg. 1992. Cytokine regulation of bone marrow natural suppressor cell activity in the suppression of lymphocyte function. Cell. Immunol. 141:398.
34. + natural suppressor cells. Int. J. Cancer 74:69.
35. Geissler, K., G. Tricot, T. Leemhuis, E. Walker, and H. E. Broxmeyer. 1989. Differentiation-inducing effect of recombinant human tumor necrosis factor alpha and gamma-interferon in vitro on blast cells from patients with acute myeloid leukemia and myeloid blast crisis of chronic myeloid leukemia. Cancer Res. 49:3057.
36. Samal, B. B., G. W. Steams, T. C. Boone, and T. Arakawa. 1993. Comparative analysis of the effects of recombinant cytokines on the growth and differentiation of ML-1, a human myelogenous leukemic cell line. Leukocyte Res. 17:299.
37. Ruhl, S., and D. H. Pluznik. 1993. Dissociation of early and late markers of murine myeloid differentiation by interferon-γ and interleukin-6. J. Cell. Physiol. 155:139.
38. Ferrajoli, A., M. Talpaz, R. Kurzrock, and Z. Estrov. 1993. Analysis of the effects of tumor necrosis factor inhibitors on human hemalopoiesis. Stem Cells 11:112.
39. Schmidt-Pak, A., G. Ip, M. A. Wright, and M. R. I. Young. 1995. Treating tumor-bearing mice with low dose interferon-γ plus tumor necrosis factor-α to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to IL-2 immunotherapy. Cancer Res. 55:885.
40. + tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte-macrophage progenitor cells with low doses of interferon-γ plus tumor necrosis factor-α. Cancer Immunol. Immunother. 38:9.
41. + cells from patients with acute non-lymphocytic leukemia. Leukocyte Lymphoma 8:389.
42. Young, M. R. I., M. A. Wright, M. Coogan, M. E. Young, and J. Bagash. 1992. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor β. Cancer Immunol. Immunother. 35:14.
43. Hogan, M. M., and S. N. Vogel. 1991. Measurement of tumor necrosis factor α and β. In Current Protocols in Immunology. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. Greene Publishing Associates and Wiley-Interscience, New York, p. 6.10.1.
44. Moore, S. C., M. A. Shaw, and S. F. Soderberg. 1992. Transforming growth factor-β is the major mediator of natural suppressor cells derived from normal bone marrow. J. Leukocyte Biol. 52:596.
45. Angulo, I., R. Rodriguez, B. Garcia, M. Medina, J. Navarro, and J. L. Subiza. 1995. Involvement of nitric oxide in bone marrow-derived natural suppressor activity: its dependence on IFN-γ. J. Immunol. 155:15.
46. + natural suppressor cells on IL-2 and IL-4 utilization in MLR. Transplantation 58:1096.